Results 251 to 260 of about 504,547 (295)

Alzheimer's Disease: Mechanisms and Therapeutic Advances

MedComm, Volume 7, Issue 11, November 2026.
Alzheimer's disease involves Aβ/tau aggregation, neuroinflammation, BBB leakage, gut–brain dysfunction, and mitochondrial damage, causing neuronal loss. Nanodelivery enables combined small‐molecule and targeted therapies. Disease‐modifying biologics/chemicals, including anti‐Aβ antibodies, raise safety and access concerns. Exercise, cognitive training,
Gaoshuang Fu, Mingmin Pan, Qingling Sun, Guangxin Yue, Tong Lei   +4 more
wiley   +1 more source

Engineering Antibodies into Targeted Chimeras: From Recognition Modules to Programmable Degraders. [PDF]

Adv Sci (Weinh)
Chen K, Hu Q.
europepmc   +1 more source

4-2 VHL-Recruiting PROTAC Inhibits the Growth and Migration of Triple Negative Breast Cancer Cells by Triggering Pyroptosis Through Fas-Mediated IL-17 Signaling. [PDF]

Drug Dev Res
Wang Q, Huang Q, Ou H, Huang T, He Y, Li P.   +5 more
europepmc   +1 more source

Cellular Morphological Profiling of PROTAC Degraders of the m6A RNA Methyltransferase METTL3. [PDF]

ACS Bio Med Chem Au
Jiang M, Ugwu CT, Wortmann L, Schloßhauer JL, Begemann C, Sievers S, Kliza KW, Wu P.   +7 more
europepmc   +1 more source

Molecular glue mediated degradation of cannabinoid receptor 1 for cancer therapy. [PDF]

NPJ Drug Discov
Kashkush A, Tadesse K, Insler B, Benhamou RI.   +3 more
europepmc   +1 more source

Identification of Clofibric Acid as a Synoviolin (SYVN1) Ligand for Proteolysis-Targeting Chimera (PROTAC) Development. [PDF]

ACS Med Chem Lett
Warren J, Munakala A, Zientek KD, Kim K, Wilmarth PA, Reddy AP, Li BX, Xiao X.   +7 more
europepmc   +1 more source

Targeted degradation of Influenza a virus nucleoprotein via aptamer-based PROTACs for antiviral therapy. [PDF]

Virulence
Li W, Ju Y, Gao Y, Peng J, Qi N.
europepmc   +1 more source